Provided by Tiger Fintech (Singapore) Pte. Ltd.

LAVA Therapeutics N.V.

1.52
-0.0100-0.65%
Volume:274.30K
Turnover:419.41K
Market Cap:39.98M
PE:-1.44
High:1.55
Open:1.53
Low:1.51
Close:1.53
52wk High:2.09
52wk Low:0.8502
Shares:26.31M
Float Shares:10.22M
Volume Ratio:2.87
T/O Rate:2.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0538
EPS(LYR):-0.9359
ROE:-90.19%
ROA:-21.30%
PB:2.01
PE(LYR):-1.62

Loading ...

LAVA Therapeutics NV Announces Date for Extraordinary General Meeting of Shareholders

Reuters
·
Aug 23

Lava Therapeutics Reports Q2 2025 Financial Results

TIPRANKS
·
Aug 20

LAVA Therapeutics NV reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 18

LAVA Therapeutics NV expected to post a loss of 25 cents a share - Earnings Preview

Reuters
·
Aug 15

LAVA Therapeutics Announces Acquisition by XOMA Corporation

TIPRANKS
·
Aug 15

LAVA Therapeutics Q2 EPS $(0.32) Misses $(0.26) Estimate

Benzinga
·
Aug 14

LAVA Therapeutics Q2 Basic EPS USD -0.32

THOMSON REUTERS
·
Aug 14

XOMA Royalty Corporation Reports Q2 2025 Net Income of $9.2M, Cash Receipts Rise to $11.7M

Reuters
·
Aug 13

Lava Therapeutics Is Maintained at Neutral by HC Wainwright & Co.

Dow Jones
·
Aug 06

LAVA Therapeutics N.v. : H.c. Wainwright Cuts Target Price to $1.24 From $1.5

THOMSON REUTERS
·
Aug 05

LAVA Therapeutics Nv : Jefferies Cuts to Hold From Buy; Cuts Target Price to $1.5 From $3

THOMSON REUTERS
·
Aug 05

LAVA Therapeutics Agrees to Acquisition by XOMA

TIPRANKS
·
Aug 04

XOMA Royalty Corp: LAVA to Initiate Wind-Down of LAVA-1266 Program

THOMSON REUTERS
·
Aug 04

XOMA Royalty Corp - Acquisition Includes CVR for 75% of Net Proceeds

THOMSON REUTERS
·
Aug 04

XOMA Royalty Corp: LAVA to Undergo Corporate Reorganization Designed to Result in XOMA Royalty Acquiring 100% of Shares in LAVA's Successor

THOMSON REUTERS
·
Aug 04

XOMA Royalty Corp - to Commence Tender Offer to Acquire LAVA by August 15, 2025

THOMSON REUTERS
·
Aug 04

XOMA Royalty Corp - LAVA to Discontinue Phase 1 Trial of LAVA-1266

THOMSON REUTERS
·
Aug 04

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

GlobeNewswire
·
Aug 04

Lava Therapeutics’ LAVA-1207 Study Terminated: Implications for Investors

TIPRANKS
·
Aug 02

LAVA Therapeutics NV Conducted Annual Shareholder Meeting

Reuters
·
Jun 14